NEW YORK (Legal Newsline) — A shareholder has filed a class action lawsuit against a supplier of medical treatments, alleging violation of federal law.
David Hovasse filed a complaint, individually and on behalf of all others similarly situated, June 8 in U.S. District Court for the Southern District of New York against Neurotrope Inc., Susanne Wilke, Daniel Alkon and Charles S. Ramat, alleging they made misleading statements regarding the company and its development of a treatment for Alzheimer's disease..
According to the complaint, Hovasse was damaged from purchasing securities at artificially inflated prices. He alleges the defendants issued materially false statements about its treatments for Alzheimer's patients in order to artificially inflate securities prices.
Hovasse seeks trial by jury, damages, interest, court costs and all further relief the court grants. He is represented by attorneys Jeremy A. Lieberman, J. Alexander Hood II and Hui M. Chang of Pomerantz LLP in New York, by Patrick Dahlstrom of Pomerantz in Chicago, and by Peretz Bronstein of Bronstein, Gerwitz & Grossman LLC in New York.
U.S. District Court for the Southern District of New York case number 1:17-cv-04313-UA